Dx Deal Roundup: A Major Proteomics Merger, Ginkgo Makes Pharma Inroads, and More Legal Woes for Illumina
As is usual at this time of year, deals in the diagnostics industry were up, both in terms of volume and value.
As is usual at this time of year, deals in the diagnostics industry were up, both in terms of volume and value.
Here are what G2 Intelligence considers the three most significant deals announced in the period from late August to early September.
The new rule put forth by the FTC and DOJ would make mergers and acquisitions much more difficult to achieve.
Seven months into the year, there were already four reported deals valued at over $1 billion in 2023, as many as in all of 2022.
Proposed rule would require businesses to undergo even more stringent review to secure regulatory approval for such deals.